David Avigan
Clinical trials sponsored by David Avigan, explained in plain language.
-
New immune therapy shows promise for tough blood cancer
Disease control Recruiting nowThis early-phase study tests a new treatment for acute myeloid leukemia (AML) that combines a personalized immune cell therapy with standard chemotherapy drugs. The therapy uses the patient's own immune cells, trained to attack the cancer, along with a vaccine to boost the immune…
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated May 26, 2026 05:57 UTC
-
New Vaccine-Drug combo targets Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests whether a personalized cancer vaccine (made by fusing a patient's own immune cells with their tumor cells) combined with the drug elranatamab is safe and works for people with multiple myeloma that has come back or stopped responding to prior treatmen…
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated May 26, 2026 05:56 UTC
-
New vaccine boosts CAR-T power against Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion) to standard CAR-T cell therapy is safe and effective for people with multiple myeloma that has returned or not responded to treatment. About 25 adults will receive the vaccine along with CAR-…
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated May 26, 2026 05:51 UTC